DNAJB1-PRKACA Fusion Kinase Peptide Vaccine

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A cancer peptide vaccine composed of a fusion peptide derived from the fusion protein DnaJ homolog subfamily B member 1-cAMP-dependent protein kinase catalytic subunit alpha fusion protein A (DNAJB1-PRKACA) that is encoded by the DNAJB1/PRKACA fusion gene, with potential immunomodulating and antineoplastic activities. Upon administration, the DNAJB1-PRKACA fusion kinase peptide vaccine may induce CD8 T cell- and CD4 T cell-mediated immune response against tumor cells expressing the DNAJB1-PRKACA fusion protein, which may result in the inhibition of proliferation in these tumor cells. The DNAJB1-PRKACA fusion protein is expressed in all fibrolamellar carcinoma (FLC) tumors and plays a key role in FLC tumorigenesis.

**Synonyms:** - DNAJB1-PRKACA Fusion Peptide Vaccine - DNAJB1-PRKACA Peptide Vaccine - FLC Peptide Vaccine - Fibrolamellar Hepatocellular Cancer Peptide Vaccine